To hear about similar clinical trials, please enter your email below

Trial Title: Evaluation of the Efficacy of Intralesional Injection of Combined Digoxin and Furosemide Versus 5 - Fluorouracil in Treatment of Plantar Warts

NCT ID: NCT05520658

Condition: Plantar Wart

Conditions: Official terms:
Warts
Foot Diseases
Fluorouracil
Digoxin
Furosemide

Study type: Interventional

Study phase: N/A

Overall status: Unknown status

Study design:

Allocation: Randomized

Intervention model: Parallel Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: combined digoxin and furosemide
Description: one session every 2 weeks for maximum 6 sessions
Arm group label: group A

Intervention type: Drug
Intervention name: 5 fluorouracil
Description: 5 fluorouracil mixed with1ml of 2% lignocaine and epinephrine one session every 2 weeks for maximum 6 sessions .
Arm group label: group B

Summary: Warts are common skin infections caused by human papillomavirus (HPV), which can cause a variety of skin presentations according to its type, site and the immune status .Nongenital warts may be presented as common, plane, plantar, filiform, or mucosal warts .Most people are affected by cutaneous warts, either plantar warts or common warts .prevalence of skin warts is between 3% and 13% and plantar warts are about 30% of skin warts in western world .Majority of cases occur in adolescent and young adults

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Age:>18 years . - Sex: both males and females will be included. - Confirmed diagnosis by clinical and dermoscopic examination of plantar warts will be made Exclusion Criteria: - Patients with history or evidenced hypersensitivity to any component used in this study. - Pregnancy & lactating. - Patients who receive immune suppressive therapy. - Patients who receive any wart treatment during the last 2 months before enrollment in the study. - Patients with systemic illness especially cardiac patients. - Patients who refused participation in the study

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: Accepts Healthy Volunteers

Locations:

Facility:
Name: Sohag University Hospital

Address:
City: Sohag
Country: Egypt

Status: Recruiting

Contact:
Last name: Osama R Elshrif, professor

Start date: July 1, 2022

Completion date: September 2022

Lead sponsor:
Agency: Sohag University
Agency class: Other

Source: Sohag University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05520658

Login to your account

Did you forget your password?